Incredible Breakthrough: Skin Patch Immunotherapy Safely Desensitizes Toddlers with Peanut Allergy, Finds Landmark Clinical Trial

Exciting findings from a global phase 3 clinical trial, including Ann & Robert H. Lurie Children's Hospital, reveal that a year-long peanut immunotherapy through a skin patch has successfully desensitized toddlers with peanut allergy. Published in the New England Journal of Medicine, this study brings hope to families. Dr. Melanie Makhija, co-author, expressed excitement, saying, "Kids who reacted to a tiny fraction of a peanut can now handle one to four peanuts. No more nutty accidents! Plus, the peanut patch proved super safe, keeping severe reactions at bay. This is a game-changer!"

Peanut allergy affects 2% of children and poses risks into adulthood. Accidental exposure to trace amounts can trigger life-threatening reactions. With no approved treatments for children under 4, this groundbreaking research offers a glimmer of hope.

Lurie Children's Hospital has been a pioneer in food allergy clinical trials since 2012. Led by Drs. Elizabeth Lippner and Abigail Lang, their program is dedicated to advancing treatments for all age groups. 

Stanley Manne Children's Research Institute at Lurie Children's Hospital is at the forefront of pediatric research, striving to transform medicine and ensure a healthier future. Ranked among the nation's top children's hospitals, Lurie Children's is a nonprofit organization dedicated to providing exceptional care for every child. It serves as the training ground for Northwestern University Feinberg School of Medicine's future pediatricians.